DB:1S1N

Stock Analysis Report

Executive Summary

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need.

Rewards

Revenue is forecast to grow 63.41% per year

Risk Analysis

Has less than 1 year of cash runway

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months

Shareholders have been diluted in the past year

+ 2 more risks


Snowflake Analysis

Mediocre balance sheet with limited growth.

Share Price & News

How has Miragen Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1S1N's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

4.9%

1S1N

0.4%

DE Biotechs

0.2%

DE Market


1 Year Return

-69.7%

1S1N

9.0%

DE Biotechs

14.4%

DE Market

Return vs Industry: 1S1N underperformed the German Biotechs industry which returned 9% over the past year.

Return vs Market: 1S1N underperformed the German Market which returned 14.4% over the past year.


Shareholder returns

1S1NIndustryMarket
7 Day4.9%0.4%0.2%
30 Day26.9%-2.1%0.9%
90 Day32.5%8.0%4.6%
1 Year-69.7%-69.7%9.2%9.0%17.9%14.4%
3 Yearn/a45.5%43.9%15.7%5.6%
5 Yearn/a12.8%10.5%23.4%6.5%

Price Volatility Vs. Market

How volatile is Miragen Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Miragen Therapeutics undervalued compared to its fair value and its price relative to the market?

1.16x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 1S1N's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 1S1N's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 1S1N is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 1S1N is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1S1N's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1S1N is good value based on its PB Ratio (1.2x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Miragen Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

11.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1S1N is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 1S1N is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 1S1N is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 1S1N's revenue (63.4% per year) is forecast to grow faster than the German market (5% per year).

High Growth Revenue: 1S1N's revenue (63.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 1S1N's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Miragen Therapeutics performed over the past 5 years?

-27.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1S1N is currently unprofitable.

Growing Profit Margin: 1S1N is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 1S1N is unprofitable, and losses have increased over the past 5 years at a rate of -27.9% per year.

Accelerating Growth: Unable to compare 1S1N's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1S1N is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 1S1N has a negative Return on Equity (-181.59%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Miragen Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: 1S1N's short term assets ($38.2M) exceed its short term liabilities ($10.4M).

Long Term Liabilities: 1S1N's short term assets ($38.2M) exceed its long term liabilities ($5.3M).


Debt to Equity History and Analysis

Debt Level: 1S1N's debt to equity ratio (39.8%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if 1S1N's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: 1S1N has a low level of unsold assets or inventory.

Debt Coverage by Assets: 1S1N's debt is covered by short term assets (assets are 4.1x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 1S1N has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 1S1N has less than a year of cash runway if free cash flow continues to reduce at historical rates of -25.2% each year


Next Steps

Dividend

What is Miragen Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.6%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 1S1N's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 1S1N's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1S1N's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1S1N's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1S1N's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.1yrs

Average management tenure


CEO

Bill Marshall (55yo)

3yrs

Tenure

US$1,987,005

Compensation

Dr. William Stuart Marshall, also known as Bill, Ph.D., Co-founded Miragen Therapeutics, Inc. in September 2007 and has been its Chief Executive Officer, President and Director since February 2017. Dr. Ma ...


CEO Compensation Analysis

Compensation vs Market: Bill's total compensation ($USD1.99M) is above average for companies of similar size in the German market ($USD412.57K).

Compensation vs Earnings: Bill's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
William Marshall
Co-Founder3yrsUS$1.99m0.58% $208.0k
Eric Olson
Co-Founder & Chairman of Scientific Advisory Board0yrsno datano data
Michael Bristow
Co-Founder & Member of the Scientific Advisory Board0yrsno datano data
Marvin Caruthers
Scientific Advisory Board Member0yrsno datano data
Jason Leverone
CFO, Treasurer & Secretary3yrsUS$259.81k0.078% $27.9k
Diana Escolar
Chief Medical Officer0yrsno datano data
Aimee Jackson
Vice President of Research4.1yrsno datano data

4.1yrs

Average Tenure

64.5yo

Average Age

Experienced Management: 1S1N's management team is considered experienced (4.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
William Marshall
Co-Founder3yrsUS$1.99m0.58% $208.0k
Eric Olson
Co-Founder & Chairman of Scientific Advisory Board0yrsno datano data
Michael Bristow
Co-Founder & Member of the Scientific Advisory Board0yrsno datano data
Marvin Caruthers
Scientific Advisory Board Member0yrsno datano data
Kevin Koch
Independent Director3yrsUS$104.78kno data
Joseph Turner
Independent Director3yrsUS$107.28kno data
Jeffrey Hatfield
Independent Chairman of the Board1.2yrsUS$102.08kno data
Victor Ambros
10.1yrsno datano data
Thomas Hughes
Independent Director3yrsUS$106.03k0.027% $9.9k
Jeffery Molkentin
Scientific Advisory Board Member0yrsno datano data

3.0yrs

Average Tenure

61yo

Average Age

Experienced Board: 1S1N's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.7%.


Top Shareholders

Company Information

Miragen Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Miragen Therapeutics, Inc.
  • Ticker: 1S1N
  • Exchange: DB
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$38.825m
  • Listing Market Cap: US$35.963m
  • Shares outstanding: 46.79m
  • Website: https://www.miragen.com

Number of Employees


Location

  • Miragen Therapeutics, Inc.
  • 6200 Lookout Road
  • Boulder
  • Colorado
  • 80301
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MGENNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDFeb 2017
1S1NDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2017
0K1RLSE (London Stock Exchange)YesCommon StockGBUSDFeb 2017

Biography

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous, ocular, and idiopathic pulmonary fibrosis; and MRG-110, an inhibitor of miR-92, a microRNA expressed in endothelial cells for the treatment of heart failure, as well as surgical incisions in high risk populations, severe lacerations, and severe burns in the United States and Japan. The company has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Servier for the development of MRG-110. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/19 23:39
End of Day Share Price2020/02/19 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.